Johnson & Johnson (JNJ): FY25 Q1 earnings call, Apr 15, 2025
No Kalshi or Polymarket word markets were listed for Johnson & Johnson’s Apr 15, 2025 earnings call (FY25 Q1). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “Caplyta”; 5 quoted, at least 25 words apart.
…Johnson's industry-leading portfolio in central nervous system disorders. With the addition of Caplyta, we have expanded our lineup of therapies with at least $5 billion-plus…
…quarter. With the successful acquisition of IntraCellular, I want to focus on Caplyta, a remarkable medicine with balanced pharmacology that delivers robust efficacy combined with…
…the supplemental new drug application to the FDA. We anticipate approval of Caplyta later this year as an adjunctive treatment for major depressive disorder, representing…
…increasing our operational sales guidance for the full year by $700 million to reflect the addition of Caplyta following the completion of the IntraCellular acquisition.
…lung cancer in the U.S., Tremfya subcutaneous induction for ulcerative colitis, and Caplyta for adjunctive major depressive disorder. We continue our rolling submission of TAR-200…
Agents: this page as TSV at /api/v1/appearances/johnson-and-johnson:2025-04-15:earnings_call · words: /api/v1/brief?appearance=johnson-and-johnson:2025-04-15:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP